BRCA1 and breast carcinoma: In another trial evaluating the triple combination of durvalumab, olaparib, and fulvestrant in hormonal receptor-positive, HER2-negative breast cancer patients, the presence of a BRCA1/2 mutation was also linked to a benefit in PFS (12.6 months [95% CI, 8.2–16.7]) vs 9.0 months [95% CI, 6.7–11.2]) compared to BRCA1/2-wildtype patients [300].